» Articles » PMID: 31054546

[Disputes and Exploration of Neoadjuvant and Adjuvant Therapy for Colon Cancer]

Overview
Date 2019 May 6
PMID 31054546
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Perioperative treatment combined with radical resection is the major approach to cure non-metastatic colon cancer. A precise evaluation and perioperative treatment would probably improve the R0 resection rate, recurrence-free survival and overall survival of colon cancer patients. Recently, individualized treatment is the mainstream due to the development of molecular pathology and multi-disciplinary therapy. The indications and course of perioperative treatment and preoperative neoadjuvant therapy of colon cancer are still in intense discussion. The present review will mainly discuss three topics. Firstly, the various reaction of adjuvant therapy to stage II colon cancer is caused by patients' heterogeneity. Choosing stratified treatment for these patients according to clinical and molecular pathological features is the future. Secondly, we discuss the adjuvant chemotherapy course for stage III colon cancer according to the Chinese Society of Clinical Oncology (CSCO) guideline and the progress of this field. Lastly, we summarize the status and significance of colon cancer neoadjuvant therapy.

Citing Articles

Progress and Perspectives in Colon Cancer Pathology, Diagnosis, and Treatments.

Alrushaid N, Khan F, Al-Suhaimi E, Elaissari A Diseases. 2023; 11(4).

PMID: 37987259 PMC: 10660546. DOI: 10.3390/diseases11040148.


Long non-coding RNA COL4A2-AS1 facilitates cell proliferation and glycolysis of colorectal cancer cells via miR-20b-5p/hypoxia inducible factor 1 alpha subunit axis.

Yu Z, Wang Y, Deng J, Liu D, Zhang L, Shao H Bioengineered. 2021; 12(1):6251-6263.

PMID: 34477476 PMC: 8806750. DOI: 10.1080/21655979.2021.1969833.


lncRNA-ATB promotes stemness maintenance in colorectal cancer by regulating transcriptional activity of the β-catenin pathway.

Yang X, Tao H, Wang C, Chen W, Hua F, Qian H Exp Ther Med. 2020; 19(4):3097-3103.

PMID: 32256798 PMC: 7086234. DOI: 10.3892/etm.2020.8558.